专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003010308A2 CONTROL OF GENE EXPRESSION 审中-公开
标题翻译：控制基因表达
公开(公告)号：WO2003010308A2
公开(公告)日：2003-02-06
申请号：PCT/GB2002/003336
申请日：2002-07-19
申请人： GENE EXPRESSION TECHNOLOGIES LIMITED , BULUWELA, Lakjaya , HOLMES, David , KAMALATI, Tahereh , WAXMAN, Jonathan , ALI, Simak
发明人： BULUWELA, Lakjaya , HOLMES, David , KAMALATI, Tahereh , WAXMAN, Jonathan , ALI, Simak
IPC分类号： C12N15/00
CPC分类号： C12N15/63
摘要： A method of suppressing the expression of a selected endogenous gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a nucleic acid binding portion which binds to a site at or associated with the selected gene and a modifying portion which comprises a polypeptide or peptidomimetic which is capable of modulating covalent modification of nucleic acid or chromatin, for example a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide. The binding of the molecule to nucleic acid may be modulated by a ligand and the molecule may comprise a ligand binding portion. The nucleic acid binding portion may be a nucleic acid binding portion of a nuclear receptor DNA binding protein.
摘要翻译：在真核细胞中抑制所选内源基因表达的方法，所述方法包括将包含核酸结合部分的多肽引入细胞（a），所述核酸结合部分结合于或与之结合的位点所选基因和修饰部分，所述修饰部分包含能够调节核酸或染色质（例如染色质失活部分）的共价修饰的多肽或肽模拟物，或（b）编码所述多肽的多核苷酸。分子与核酸的结合可以由配体调节，并且分子可以包含配体结合部分。核酸结合部分可以是核受体DNA结合蛋白的核酸结合部分。

2. 发明申请

WO03010308A3 CONTROL OF GENE EXPRESSION 审中-公开
标题翻译：基因表达控制
公开(公告)号：WO03010308A3
公开(公告)日：2003-05-08
申请号：PCT/GB0203336
申请日：2002-07-19
申请人： GENE EXPRESSION TECHNOLOGIES L , BULUWELA LAKJAYA , HOLMES DAVID , KAMALATI TAHEREH , WAXMAN JONATHAN , ALI SIMAK
发明人： BULUWELA LAKJAYA , HOLMES DAVID , KAMALATI TAHEREH , WAXMAN JONATHAN , ALI SIMAK
IPC分类号： A61P35/00 , C12N15/63 , C12N15/11 , A01K67/027 , A61K38/16 , A61K47/48 , C07K14/47 , C12N5/10 , C12N15/67 , C12N15/82
CPC分类号： C12N15/63
摘要： A method of suppressing the expression of a selected endogenous gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a nucleic acid binding portion which binds to a site at or associated with the selected gene and a modifying portion which comprises a polypeptide or peptidomimetic which is capable of modulating covalent modification of nucleic acid or chromatin, for example a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide. The binding of the molecule to nucleic acid may be modulated by a ligand and the molecule may comprise a ligand binding portion. The nucleic acid binding portion may be a nucleic acid binding portion of a nuclear receptor DNA binding protein.
摘要翻译：一种抑制真核细胞中所选择的内源基因表达的方法，该方法包括将细胞（a）包含与选定基因位点或与所选基因相关的位点结合的核酸结合部分的多肽和修饰部分包括能够调节核酸或染色质共价修饰的多肽或拟肽，例如染色质失活部分，或（b）编码所述多肽的多核苷酸。分子与核酸的结合可以通过配体调节，并且分子可以包含配体结合部分。核酸结合部分可以是核受体DNA结合蛋白的核酸结合部分。

3. 发明申请

WO2009019493A1 ANTIBODIES BINDING HUMAN PROSTATE EPITHELIAL CELLS 审中-公开
标题翻译：抗体结合人前列腺上皮细胞
公开(公告)号：WO2009019493A1
公开(公告)日：2009-02-12
申请号：PCT/GB2008/002733
申请日：2008-08-11
申请人： IMPERIAL INNOVATIONS LIMITED , KAMALATI, Tahereh , BULUWELA, Lakjaya
发明人： KAMALATI, Tahereh , BULUWELA, Lakjaya
IPC分类号： C07K16/30
CPC分类号： C07K16/3069 , C07K2317/565 , C07K2317/622 , C07K2317/73
摘要： An isolated recombinant antibody that binds to a normal human prostate epithelial cell and/or cultured human prostate tumour cell to a greater extent than to a prostate fibroblast or muscle cell, the recombinant antibody comprising at least one, two, three, four or five, or six, CDR sequence selected from a) GFTFSSYA (CDRl sequence); ISYDGSNK (CDR2 sequence); ARVYFRL WGQGTLVTV (CDR3 sequence); SSNIGSNY C(CDRl sequence); RNN (CDR2 sequence); AAWDDSLPVFGGGTKLTVLGAAA (CDR3 sequence); with no or up to 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 conservative or non-conservative amino acid substitutions in each CDR sequence; or b) GDSVSSNSAA (CDRl sequence); TYYRSKWYN (CDR2 sequence); ARLVDASFDYWGQGTLVTV (CDR3 sequence); QGISSW (CDRl sequence); AAS (CDR2 sequence); QQANSFRTFGQGTKVEIKRAAA (CDR3 sequence); with no or up to 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 conservative or non-conservative amino acid substitutions in each CDR sequence. The antibody is considered to be useful in imaging, diagnosis and treatment of cancer, particularly prostate cancer.
摘要翻译：一种分离的重组抗体，其比前列腺成纤维细胞或肌肉细胞更大程度地与正常人前列腺上皮细胞和/或培养的人前列腺肿瘤细胞结合，所述重组抗体包含至少一个，二个，三个，四个或五个，或6个，选自a）GFTFSSYA（CDR1序列）的CDR序列; ISYDGSNK（CDR2序列）; ARVYFRL WGQGTLVTV（CDR3序列）; SSNIGSNY C（CDR1序列）; RNN（CDR2序列）; AAWDDSLPVFGGGTKLTVLGAAA（CDR3序列）; 在每个CDR序列中没有或至多1,2,3,4,5,6,7,8,9或10个保守或非保守氨基酸取代; 或b）GDSVSSNSAA（CDR1序列）; TYYRSKWYN（CDR2序列）; ARLVDASFDYWGQGTLVTV（CDR3序列）; QGISSW（CDR1序列）; AAS（CDR2序列）; QQANSFRTFGQGTKVEIKRAAA（CDR3序列）; 在每个CDR序列中没有或至多1,2,3,4,5,6,7,8,9或10个保守或非保守氨基酸取代。认为该抗体可用于成像，诊断和治疗癌症，特别是前列腺癌。

4. 发明申请

WO1995002057A1 PROTEIN TYROSINE KINASE AND LIGANDS THEREOF 审中-公开
标题翻译：蛋白酪氨酸激酶及其配体
公开(公告)号：WO1995002057A1
公开(公告)日：1995-01-19
申请号：PCT/GB1994001479
申请日：1994-07-08
申请人： THE INSTITUTE OF CANCER RESEARCH , THE WELLCOME FOUNDATION LIMITED , GUSTERSON, Barry, Austin , CROMPTON, Mark, Roger , MITCHELL, Philip, John , BARKER, Karen, Tracey , KAMALATI, Tahereh , PAGE, Martin, John , SPENCE, Paul
发明人： THE INSTITUTE OF CANCER RESEARCH , THE WELLCOME FOUNDATION LIMITED
IPC分类号： C12N15/54
CPC分类号： A61K31/70 , A61K31/275 , A61K31/35 , A61K31/55 , A61K38/00 , A61K47/62 , C12N9/1205 , C12Q1/48 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/573
摘要： The invention relates to a novel tyrosine kinase designated b &cir& _r &cir& _k &cir& _ and the use of this tyrosine kinase in the development of diagnostic and therapeutic approaches to cancer. The novel tyrosine kinase was isolated from a human metastatic breast tumour using a PCR based differential screening approach and has the deduced amino acid sequence shown in SEQ ID NO. 2.
摘要翻译：本发明涉及一种新的酪氨酸激酶，其命名为b＆cir＆_ r＆cir＆_k＆cir＆_，以及该酪氨酸激酶在癌症诊断和治疗方法开发中的应用。使用基于PCR的差异筛选方法从人转移性乳腺肿瘤分离出新的酪氨酸激酶，并且具有SEQ ID NO：1所示的推导的氨基酸序列。 2。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式